SQI Diagnostics Systems Inc.   
Ms. Kate Smith, VP, Technology 36 Meteor Dr.   
Toronto, ON M9W 1A4   
Canada

Re: k140691 Trade/Device Name: Ig_plex Celiac DGP Panel Regulation Number: 21 CFR 866.5660 Regulation Name: Multiple autoantibodies immunological test system Regulatory Class: II Product Codes: MVM, MST, NSU Dated: October 6, 2014 Received: October 7, 2014

Dear Ms. Smith:

We have reviewed your Section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA‚Äôs issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act‚Äôs requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, ‚ÄúMisbranding by reference to premarket notification‚Äù (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH‚Äôs Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Maria M. Chan -S

Maria M. Chan, Ph. D.   
Director   
Division of Immunology and Hematology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

Enclosure

0'%123
	4!
 

-! 5!
	! !"	#\$%--#

#  ! " "# -  \$

8
!5
9!
9,

!:!!
6
8!
!;2
!5
5
6
'&&0\$

# %! &"'  -( "!-- ' !!) '\*\$%

8!
4!
!
6
8
599!5
6
6

!!

 !!
/&
8
!
!!.
59
8! !

! !;
5.
!58
!\*

5!.
8!


8!

!!!

59!! 
! !;
8!
599!5
6
6\$
!
5!
!
8
4!
!!

,
8!
!5 6
8
6
599!5.
59
!
6
!5
8
4!.
"

-!!
6
!98


! 5! 

-
 665!
6
8!6
6
665! !;2
!5
5
13
66 -		

!	"
	"#		\$#	 
	#	"	#" 	%&'#
(

# Section 8.0 (revised): 510(k) Summary

# 510(k) Summary

# Name:

SQI Diagnostics Systems Inc.

# Address:

36 Meteor Drive   
Toronto, Ontario   
Canada   
M9W 1A4   
416-674-9500 x 329   
416-674-9300   
Kate Smith   
ksmith@sqidiagnostics.com   
November 4, 2014   
Phone:   
FAX:   
Contact:   
Email:   
Date Prepared:

Trade Name: Common Name: Classification: Product Code:

Ig_plex¬Æ Celiac DGP Panel   
Multiplexed DGP IgA, DGP IgG, tTG IgA and tTG IgG Microarray Assay   
Class II   
MST: Antibodies, gliadin   
MVM: Autoantibodies, Endomysial (Tissue Transglutaminase)   
NSU: Instrumentation for Clinical Multiplex Test Systems   
21 CFR ¬ß866.5750: Radioallergosorbent (RAST) immunological test   
system   
21 CFR ¬ß866.5660: Multiple autoantibodies immunological test system   
Transglutaminase)   
21 CFR ¬ß862.2570: Instrumentation for Clinical Multiplex Test Systems

# Regulation Number:

# Substantial Equivalence:

Inova Diagnostics, Inc. assays:

ÔÇß Quanta Lite‚Ñ¢ Gliadin IgA II (k052143)   
ÔÇß Quanta Lite‚Ñ¢ Gliadin IgG II (k052142)   
ÔÇß Quanta Lite‚Ñ¢ h-tTG IgA ELISA (k011566)   
ÔÇß Quanta Lite‚Ñ¢ h-tTG IgG ELISA (k011570)   
SQI Diagnostics SQiDworks‚Ñ¢ Diagnostics Platform (k102490)

# Intended Use

The Ig_plex¬Æ Celiac DGP Panel is an in vitro diagnostic test for the semi-quantitative detection of the IgA and IgG immunoglobulin classes of antibodies to deamidated gliadin peptide (DGP) and tissue transglutaminase (tTG) in human serum. The test is intended for use in clinical laboratories as an aid in the diagnosis of celiac disease in conjunction with other laboratory and clinical findings, and requires the sqid- $\pmb { \chi } ^ { \mathsf { T M } }$ system.

# Device Description

The Ig_plex Celiac DGP Panel is a consumable reagent kit. It is designed to run on the sqid-X system. The kit includes a microarray plate, reporter mix, standards, controls, sample diluents, wash buffer concentrates and a CD-ROM.

The assay detects the presences of the IgA and IgG classes of anti-DGP antibody, and the IgA and IgG classes of anti-tissue transglutaminase antibody. This is performed in an integrated fashion on the sqid-X system that reports all analytes simultaneously to aid in the diagnosis of celiac disease.

The system is a multiplex immunoassay analyzer that semi-automates the protocol of a specific Ig_plex assay from plate washing to reporting of all assay markers for each individual patient sample. The system combines manual liquid handling (samples and reagents) with automated steps for washing, scanning, data analyses and reporting. Results for each patient sample are obtained simultaneously for each of the four markers using the results from one well containing one aliquot of the patient‚Äôs serum. Results are reported independently.

# Comparison to Predicates

The Ig_plex Celiac DGP Panel uses the same ELISA assay principles of capture antigen, sample addition/incubation, reporter addition/incubation and fluorescent signal interpretation as the predicates with the improvement of multiplexing. The intended use of the Ig_plex Celiac DGP Panel and its predicates are all to aid in the diagnosis of celiac disease.

# Test Studies

A series of test studies were conducted in support of the comparability, safety and effectiveness of the Ig_plex Celiac DGP Panel and its predicates. The studies completed with the results as shown in the following pages.

126 presumed normal, 56 other autoimmune disease, and 110 celiac patient specimens were evaluated for accurate determination of each analyte‚Äôs cut-off in the Ig_plex Celiac DGP Panel (see Table 1).

Samples are negative for the analyte if the result is less than or equal to the respective cut-off and positive if the result is greater than the respective cut-off.

The system reports values within the Assay Measuring Range (linear range) of the assay as shown in Table 1.

Table 1: Cut-Off Values and Assay Measuring Range   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Cut-Off Values(U/mL)</td><td rowspan=1 colspan=1>Assay MeasuringRange (U/mL)</td></tr><tr><td rowspan=1 colspan=1>tTG IgA</td><td rowspan=1 colspan=1>20.0</td><td rowspan=1 colspan=1>16.0 - 140.0</td></tr><tr><td rowspan=1 colspan=1>tTG IgG</td><td rowspan=1 colspan=1>36.0</td><td rowspan=1 colspan=1>24.0 - 100.0</td></tr><tr><td rowspan=1 colspan=1>DGP IgA</td><td rowspan=1 colspan=1>15.0</td><td rowspan=1 colspan=1>8.0 - 110.0</td></tr><tr><td rowspan=1 colspan=1>DGP IgG</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>9.0 - 120.0</td></tr></table>

# Analytical Interference

Two (2) celiac diagnosed samples and one (1) negative sample were evaluated for levels of interferents above physiological ranges to establish analytical specificity. Table 2: lists the levels $( \mathsf { m g / m L } )$ of interferents reporting clinically acceptable recoveries (bias $\leq 1 5 \% )$ ).

Table 2: Analytical Interference   

<table><tr><td rowspan=2 colspan=1>Analyte</td><td rowspan=1 colspan=4>Interferent (mg/mL)</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>Human IgG</td></tr><tr><td rowspan=1 colspan=1>tTG IgA</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>5.00</td><td rowspan=1 colspan=1>5.00</td><td rowspan=1 colspan=1>0.50</td></tr><tr><td rowspan=1 colspan=1>tTG IgG</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>5.00</td><td rowspan=1 colspan=1>5.00</td><td rowspan=1 colspan=1>0.50</td></tr><tr><td rowspan=1 colspan=1>DGP IgA</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>5.00</td><td rowspan=1 colspan=1>5.00</td><td rowspan=1 colspan=1>0.50</td></tr><tr><td rowspan=1 colspan=1>DGP IgG</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>5.00</td><td rowspan=1 colspan=1>5.00</td><td rowspan=1 colspan=1>0.50</td></tr></table>

# Sensitivity and Specificity

The sensitivity and specificity of the Ig_plex Celiac DGP Panel for each of the four analytes were determined from 378 samples including: 128 celiac biopsy confirmed samples, and 250 samples from other autoimmune diseases including rheumatic and infectious diseases. The resulting clinical sensitivities and specificities are shown in Table 3.

Table 3: Clinical Sensitivity and Specificity   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>% Sensitivity (95% CI)</td><td rowspan=1 colspan=1>% Specificity (95% CI)</td></tr><tr><td rowspan=1 colspan=1>tTG IgA</td><td rowspan=1 colspan=1>98.4 (97.3-99.5%)</td><td rowspan=1 colspan=1>100.0 (100.0-100.0%)</td></tr><tr><td rowspan=1 colspan=1>tTG IgG</td><td rowspan=1 colspan=1>46.9 (42.5-51.3%)</td><td rowspan=1 colspan=1>98.8 (98.1-99.5%)</td></tr><tr><td rowspan=1 colspan=1>DGP IgA</td><td rowspan=1 colspan=1>79.7 (76.1-83.2%)</td><td rowspan=1 colspan=1>99.2 (98.6-99.8%)</td></tr><tr><td rowspan=1 colspan=1>DGP IgG</td><td rowspan=1 colspan=1>89.1 (86.3-91.8%)</td><td rowspan=1 colspan=1>99.6 (99.2-100.0%)</td></tr></table>

The cross-reactivity with other autoimmune diseases was determined by analyzing the 250 patient samples diagnosed with various autoimmune diseases that were tested for the sensitivity and specificity study. Specificity was calculated for each disease with the results as shown in Table 4.

Table 4: Specificity of Other Autoimmune Diseases   

<table><tr><td rowspan=2 colspan=1>Disease Classification</td><td rowspan=1 colspan=4>Specificity (%)</td></tr><tr><td rowspan=1 colspan=1>tTG IgA</td><td rowspan=1 colspan=1>tTG IgG</td><td rowspan=1 colspan=1>DGP IgA</td><td rowspan=1 colspan=1>DGP IgG</td></tr><tr><td rowspan=1 colspan=1>SLE</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>96.7</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Sjogren&#x27;s Syndrome</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Wheat Allergy</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>IBD (Crohn&#x27;s Disease)</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>IBD (Ulcerative Colitis)</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Lactose Intolerant</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>87.5</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Osteoarthritis</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Celiac 1¬∞ Relative</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>IgA Deficient, non-Celiac</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>66.7</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Arthritis (RA)</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>96.2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>96.2</td></tr><tr><td rowspan=1 colspan=1>Hashimoto&#x27;s Thyroiditis</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>95.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Vasculitis</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>EBV Positive</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Syphilis Positive</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Diabetes Mellitus Type 2</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Type 1 Diabetes</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Grave&#x27;s Thyroiditis</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Suspected celiac, normal biopsy</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Other Autoimmune Diseases</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.0</td></tr></table>

# Method Comparison

Method comparisons consisted of testing 229 positive celiac patient samples, 132 presumptively normal samples, and 18 other autoimmune disease samples with the Ig_plex Celiac DGP Panel and with a commercially available predicate method for each of the analytes. The results are presented in Table 5.

Table 5: Method Agreement   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>% Positive Agreement(95% CI)</td><td rowspan=1 colspan=1>% Negative Agreement(95% CI)</td><td rowspan=1 colspan=1>% Overall Agreement(95% Cl)</td></tr><tr><td rowspan=1 colspan=1>tTG IgA</td><td rowspan=1 colspan=1>100.0 (97.2-100.0%)</td><td rowspan=1 colspan=1>87.9 (82.5-91.8%)</td><td rowspan=1 colspan=1>92.9 (89.5-95.2%)</td></tr><tr><td rowspan=1 colspan=1>tTG IgG</td><td rowspan=1 colspan=1>94.1 (84.1-98.0%)</td><td rowspan=1 colspan=1>84.6 (79.3-88.7%)</td><td rowspan=1 colspan=1>86.3 (81.8-89.9%)</td></tr><tr><td rowspan=1 colspan=1>DGP IgA</td><td rowspan=1 colspan=1>93.3 (87.8-96.5%)</td><td rowspan=1 colspan=1>95.1 (90.9-97.4%)</td><td rowspan=1 colspan=1>94.3 (91.2-96.4%)</td></tr><tr><td rowspan=1 colspan=1>DGP IgG</td><td rowspan=1 colspan=1>98.5 (94.6-99.6%)</td><td rowspan=1 colspan=1>90.3 (85.3-93.7%)</td><td rowspan=1 colspan=1>93.6 (90.4-95.7%)</td></tr></table>

# Precision and Reproducibility

The precision of Ig_plex Celiac DGP Panel was evaluated according to CLSI EP5-A2 -Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline‚ÄîSecond Edition.

The inter-assay precision study consisted of testing negative and positive samples covering the entire measuring range in replicates of two, twice a day for 20 days by two operators using one lot on one system.

The lot-to-lot reproducibility study consisted of testing negative and positive samples covering the entire measuring range in replicates of five per kit, using two kits per lot, on three kit lots on one instrument.

The multi-instrument study consisted of testing negative and positive samples covering the entire measuring range in replicates of five per kit, using two kits per lot, on three kit lots, on three different instruments at three sites.

Table 6 through Table 16 (following pages) present the precision and reproducibility results for each analyte.

Table 6: tTG IgA Inter-assay Precision and Reproducibility   

<table><tr><td rowspan=2 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>17.29</td><td rowspan=1 colspan=1>0.643</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.666</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.926</td><td rowspan=1 colspan=1>5.4%</td></tr><tr><td rowspan=1 colspan=1>24.46</td><td rowspan=1 colspan=1>0.997</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>0.624</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>0.534</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>1.292</td><td rowspan=1 colspan=1>5.3%</td></tr><tr><td rowspan=1 colspan=1>32.35</td><td rowspan=1 colspan=1>1.615</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>0.557</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.708</td><td rowspan=1 colspan=1>5.3%</td></tr><tr><td rowspan=1 colspan=1>35.19</td><td rowspan=1 colspan=1>1.383</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.744</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>1.710</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>2.321</td><td rowspan=1 colspan=1>6.6%</td></tr><tr><td rowspan=1 colspan=1>43.29</td><td rowspan=1 colspan=1>1.946</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>1.790</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>2.644</td><td rowspan=1 colspan=1>6.1%</td></tr><tr><td rowspan=1 colspan=1>60.05</td><td rowspan=1 colspan=1>3.261</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>1.417</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>1.207</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>3.754</td><td rowspan=1 colspan=1>6.3%</td></tr><tr><td rowspan=1 colspan=1>85.55</td><td rowspan=1 colspan=1>4.365</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>3.400</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>5.533</td><td rowspan=1 colspan=1>6.5%</td></tr><tr><td rowspan=1 colspan=1>120.73</td><td rowspan=1 colspan=1>7.515</td><td rowspan=1 colspan=1>6.2%</td><td rowspan=1 colspan=1>1.898</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>2.917</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>8.282</td><td rowspan=1 colspan=1>6.9%</td></tr><tr><td rowspan=1 colspan=1>136.63</td><td rowspan=1 colspan=1>6.419</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>3.287</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>1.841</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>7.444</td><td rowspan=1 colspan=1>5.4%</td></tr></table>

Table 7: tTG IgA Lot-to-Lot Precision and Reproducibility   

<table><tr><td rowspan=1 colspan=3>Lot-to-Lot Reproducibility(n=30)</td></tr><tr><td rowspan=1 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>11.91</td><td rowspan=1 colspan=1>0.651</td><td rowspan=1 colspan=1>5.5%</td></tr><tr><td rowspan=1 colspan=1>19.54</td><td rowspan=1 colspan=1>1.140</td><td rowspan=1 colspan=1>5.8%</td></tr><tr><td rowspan=1 colspan=1>32.6</td><td rowspan=1 colspan=1>2.191</td><td rowspan=1 colspan=1>6.7%</td></tr><tr><td rowspan=1 colspan=1>38.05</td><td rowspan=1 colspan=1>2.311</td><td rowspan=1 colspan=1>6.1%</td></tr><tr><td rowspan=1 colspan=1>44.31</td><td rowspan=1 colspan=1>3.018</td><td rowspan=1 colspan=1>6.8%</td></tr><tr><td rowspan=1 colspan=1>60.49</td><td rowspan=1 colspan=1>3.709</td><td rowspan=1 colspan=1>6.1%</td></tr><tr><td rowspan=1 colspan=1>95.28</td><td rowspan=1 colspan=1>4.301</td><td rowspan=1 colspan=1>4.5%</td></tr><tr><td rowspan=1 colspan=1>135.2</td><td rowspan=1 colspan=1>9.164</td><td rowspan=1 colspan=1>6.8%</td></tr></table>

Table 8: tTG IgA Instrument-to-Instrument Precision and Reproducibility   

<table><tr><td rowspan=1 colspan=3>Instrument-to-InstrumentReproducibility (n=90)</td></tr><tr><td rowspan=1 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>19.22</td><td rowspan=1 colspan=1>1.064</td><td rowspan=1 colspan=1>5.5%</td></tr><tr><td rowspan=1 colspan=1>32.12</td><td rowspan=1 colspan=1>2.040</td><td rowspan=1 colspan=1>6.4%</td></tr><tr><td rowspan=1 colspan=1>46.76</td><td rowspan=1 colspan=1>3.998</td><td rowspan=1 colspan=1>8.6%</td></tr><tr><td rowspan=1 colspan=1>65.78</td><td rowspan=1 colspan=1>4.236</td><td rowspan=1 colspan=1>6.4%</td></tr></table>

Table 9: tTG IgG Inter-assay Precision and Reproducibility   

<table><tr><td rowspan=2 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>27.56</td><td rowspan=1 colspan=1>1.036</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>1.187</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.691</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>1.721</td><td rowspan=1 colspan=1>6.2%</td></tr><tr><td rowspan=1 colspan=1>28.22</td><td rowspan=1 colspan=1>2.011</td><td rowspan=1 colspan=1>7.1%</td><td rowspan=1 colspan=1>1.182</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>1.091</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>2.575</td><td rowspan=1 colspan=1>9.1%</td></tr><tr><td rowspan=1 colspan=1>33.72</td><td rowspan=1 colspan=1>2.538</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.016</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>2.734</td><td rowspan=1 colspan=1>8.1%</td></tr><tr><td rowspan=1 colspan=1>40.65</td><td rowspan=1 colspan=1>2.297</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>2.189</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>1.393</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>3.465</td><td rowspan=1 colspan=1>8.5%</td></tr><tr><td rowspan=1 colspan=1>48.39</td><td rowspan=1 colspan=1>3.397</td><td rowspan=1 colspan=1>7.0%</td><td rowspan=1 colspan=1>1.490</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>3.710</td><td rowspan=1 colspan=1>7.7%</td></tr><tr><td rowspan=1 colspan=1>50.61</td><td rowspan=1 colspan=1>3.189</td><td rowspan=1 colspan=1>6.3%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.386</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>3.478</td><td rowspan=1 colspan=1>6.9%</td></tr><tr><td rowspan=1 colspan=1>78.54</td><td rowspan=1 colspan=1>4.840</td><td rowspan=1 colspan=1>6.2%</td><td rowspan=1 colspan=1>1.995</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>2.994</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>6.031</td><td rowspan=1 colspan=1>7.7%</td></tr><tr><td rowspan=1 colspan=1>87.78</td><td rowspan=1 colspan=1>3.717</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>2.442</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>3.281</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>5.527</td><td rowspan=1 colspan=1>6.3%</td></tr><tr><td rowspan=1 colspan=1>99.21</td><td rowspan=1 colspan=1>6.200</td><td rowspan=1 colspan=1>6.2%</td><td rowspan=1 colspan=1>3.507</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>3.218</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>7.817</td><td rowspan=1 colspan=1>7.9%</td></tr></table>

Table 10: tTG IgG Lot-to-Lot Precision and Reproducibility   

<table><tr><td rowspan=1 colspan=3>Lot-to-Lot Reproducibility(n=30)</td></tr><tr><td rowspan=1 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>29.58</td><td rowspan=1 colspan=1>1.962</td><td rowspan=1 colspan=1>6.6%</td></tr><tr><td rowspan=1 colspan=1>34.4</td><td rowspan=1 colspan=1>2.803</td><td rowspan=1 colspan=1>8.1%</td></tr><tr><td rowspan=1 colspan=1>43.83</td><td rowspan=1 colspan=1>2.981</td><td rowspan=1 colspan=1>6.8%</td></tr><tr><td rowspan=1 colspan=1>50.13</td><td rowspan=1 colspan=1>4.737</td><td rowspan=1 colspan=1>9.5%</td></tr><tr><td rowspan=1 colspan=1>62.01</td><td rowspan=1 colspan=1>4.698</td><td rowspan=1 colspan=1>7.6%</td></tr><tr><td rowspan=1 colspan=1>65.06</td><td rowspan=1 colspan=1>4.871</td><td rowspan=1 colspan=1>7.5%</td></tr></table>

# Table 11: tTG IgG Instrument-to-Instrument Precision and Reproducibility

<table><tr><td rowspan=1 colspan=3>Instrument-to-InstrumentReproducibility (n=90)</td></tr><tr><td rowspan=1 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>29.52</td><td rowspan=1 colspan=1>2.927</td><td rowspan=1 colspan=1>9.9%</td></tr><tr><td rowspan=1 colspan=1>47.76</td><td rowspan=1 colspan=1>4.681</td><td rowspan=1 colspan=1>9.8%</td></tr><tr><td rowspan=1 colspan=1>51.00</td><td rowspan=1 colspan=1>5.157</td><td rowspan=1 colspan=1>10.1%</td></tr><tr><td rowspan=1 colspan=1>63.68</td><td rowspan=1 colspan=1>6.325</td><td rowspan=1 colspan=1>9.9%</td></tr></table>

Table 12: DGP IgA Inter-assay Precision and Reproducibility   

<table><tr><td rowspan=2 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>9.13</td><td rowspan=1 colspan=1>0.426</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>0.305</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.524</td><td rowspan=1 colspan=1>5.7%</td></tr><tr><td rowspan=1 colspan=1>15.83</td><td rowspan=1 colspan=1>0.637</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>0.268</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.311</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.758</td><td rowspan=1 colspan=1>4.8%</td></tr><tr><td rowspan=1 colspan=1>20.28</td><td rowspan=1 colspan=1>0.704</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.983</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.209</td><td rowspan=1 colspan=1>6.0%</td></tr><tr><td rowspan=1 colspan=1>28.47</td><td rowspan=1 colspan=1>1.680</td><td rowspan=1 colspan=1>5.9%</td><td rowspan=1 colspan=1>1.228</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.660</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>2.183</td><td rowspan=1 colspan=1>7.7%</td></tr><tr><td rowspan=1 colspan=1>36.20</td><td rowspan=1 colspan=1>2.017</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>1.143</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.586</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>2.391</td><td rowspan=1 colspan=1>6.6%</td></tr><tr><td rowspan=1 colspan=1>47.84</td><td rowspan=1 colspan=1>1.834</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>2.588</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>1.155</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>3.375</td><td rowspan=1 colspan=1>7.1%</td></tr><tr><td rowspan=1 colspan=1>54.63</td><td rowspan=1 colspan=1>2.966</td><td rowspan=1 colspan=1>5.4%</td><td rowspan=1 colspan=1>1.816</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>1.561</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>3.812</td><td rowspan=1 colspan=1>7.0%</td></tr><tr><td rowspan=1 colspan=1>78.94</td><td rowspan=1 colspan=1>4.749</td><td rowspan=1 colspan=1>6.0%</td><td rowspan=1 colspan=1>3.474</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>1.430</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>6.055</td><td rowspan=1 colspan=1>7.7%</td></tr><tr><td rowspan=1 colspan=1>104.24</td><td rowspan=1 colspan=1>3.800</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>5.391</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>6.596</td><td rowspan=1 colspan=1>6.3%</td></tr></table>

Table 13: DGP IgA Lot-to-Lot Precision and Reproducibility   

<table><tr><td rowspan=1 colspan=3>Lot-to-Lot Reproducibility(n=30)</td></tr><tr><td rowspan=1 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>9.35</td><td rowspan=1 colspan=1>0.878</td><td rowspan=1 colspan=1>9.4%</td></tr><tr><td rowspan=1 colspan=1>11.9</td><td rowspan=1 colspan=1>0.858</td><td rowspan=1 colspan=1>7.2%</td></tr><tr><td rowspan=1 colspan=1>15.04</td><td rowspan=1 colspan=1>0.908</td><td rowspan=1 colspan=1>6.0%</td></tr><tr><td rowspan=1 colspan=1>16.65</td><td rowspan=1 colspan=1>1.141</td><td rowspan=1 colspan=1>6.9%</td></tr><tr><td rowspan=1 colspan=1>18.66</td><td rowspan=1 colspan=1>0.878</td><td rowspan=1 colspan=1>4.7%</td></tr><tr><td rowspan=1 colspan=1>20.07</td><td rowspan=1 colspan=1>1.002</td><td rowspan=1 colspan=1>5.0%</td></tr><tr><td rowspan=1 colspan=1>59.91</td><td rowspan=1 colspan=1>3.435</td><td rowspan=1 colspan=1>5.7%</td></tr><tr><td rowspan=1 colspan=1>65.01</td><td rowspan=1 colspan=1>4.623</td><td rowspan=1 colspan=1>7.1%</td></tr></table>

Table 14: DGP IgA Instrument-to-Instrument Precision and Reproducibility   

<table><tr><td rowspan=1 colspan=3>Instrument-to-InstrumentReproducibility (n=90)</td></tr><tr><td rowspan=1 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>8.58</td><td rowspan=1 colspan=1>0.823</td><td rowspan=1 colspan=1>9.6%</td></tr><tr><td rowspan=1 colspan=1>16.64</td><td rowspan=1 colspan=1>1.300</td><td rowspan=1 colspan=1>7.8%</td></tr><tr><td rowspan=1 colspan=1>18.73</td><td rowspan=1 colspan=1>1.410</td><td rowspan=1 colspan=1>7.5%</td></tr><tr><td rowspan=1 colspan=1>21.01</td><td rowspan=1 colspan=1>1.661</td><td rowspan=1 colspan=1>7.9%</td></tr><tr><td rowspan=1 colspan=1>61.71</td><td rowspan=1 colspan=1>5.552</td><td rowspan=1 colspan=1>9.0%</td></tr></table>

Table 15: DGP IgG Inter-assay Precision and Reproducibility   

<table><tr><td rowspan=2 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>15.38</td><td rowspan=1 colspan=1>0.712</td><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>0.465</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.695</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>1.098</td><td rowspan=1 colspan=1>7.1%</td></tr><tr><td rowspan=1 colspan=1>22.09</td><td rowspan=1 colspan=1>1.006</td><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>1.006</td><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>0.753</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>1.610</td><td rowspan=1 colspan=1>7.3%</td></tr><tr><td rowspan=1 colspan=1>31.89</td><td rowspan=1 colspan=1>1.261</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>0.609</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.909</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>1.669</td><td rowspan=1 colspan=1>5.2%</td></tr><tr><td rowspan=1 colspan=1>41.51</td><td rowspan=1 colspan=1>2.018</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>0.605</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.687</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>2.216</td><td rowspan=1 colspan=1>5.3%</td></tr><tr><td rowspan=1 colspan=1>50.08</td><td rowspan=1 colspan=1>2.606</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>1.416</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>1.166</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>3.187</td><td rowspan=1 colspan=1>6.4%</td></tr><tr><td rowspan=1 colspan=1>71.35</td><td rowspan=1 colspan=1>2.737</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>2.641</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>3.804</td><td rowspan=1 colspan=1>5.3%</td></tr><tr><td rowspan=1 colspan=1>85.57</td><td rowspan=1 colspan=1>3.215</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>2.342</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>3.977</td><td rowspan=1 colspan=1>4.6%</td></tr><tr><td rowspan=1 colspan=1>119.12</td><td rowspan=1 colspan=1>6.063</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>2.265</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>6.472</td><td rowspan=1 colspan=1>5.4%</td></tr></table>

Table 16: DGP IgG Lot-to-Lot Precision and Reproducibility   

<table><tr><td rowspan=1 colspan=3>Lot-to-Lot Reproducibility(n=30)</td></tr><tr><td rowspan=1 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>11.74</td><td rowspan=1 colspan=1>0.601</td><td rowspan=1 colspan=1>5.1%</td></tr><tr><td rowspan=1 colspan=1>15.42</td><td rowspan=1 colspan=1>0.889</td><td rowspan=1 colspan=1>5.8%</td></tr><tr><td rowspan=1 colspan=1>17.98</td><td rowspan=1 colspan=1>0.841</td><td rowspan=1 colspan=1>4.7%</td></tr><tr><td rowspan=1 colspan=1>33.08</td><td rowspan=1 colspan=1>2.088</td><td rowspan=1 colspan=1>6.3%</td></tr><tr><td rowspan=1 colspan=1>46.42</td><td rowspan=1 colspan=1>2.127</td><td rowspan=1 colspan=1>4.6%</td></tr><tr><td rowspan=1 colspan=1>74.15</td><td rowspan=1 colspan=1>4.999</td><td rowspan=1 colspan=1>6.7%</td></tr><tr><td rowspan=1 colspan=1>85.92</td><td rowspan=1 colspan=1>5.118</td><td rowspan=1 colspan=1>6.0%</td></tr><tr><td rowspan=1 colspan=1>116.14</td><td rowspan=1 colspan=1>5.185</td><td rowspan=1 colspan=1>4.5%</td></tr></table>

Table 17: DGP IgG Instrument-to-Instrument Precision and Reproducibility   

<table><tr><td rowspan=1 colspan=3>Instrument-to-InstrumentReproducibility (n=90)</td></tr><tr><td rowspan=1 colspan=1>Mean(U/mL)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>11.28</td><td rowspan=1 colspan=1>0.981</td><td rowspan=1 colspan=1>8.7%</td></tr><tr><td rowspan=1 colspan=1>16.61</td><td rowspan=1 colspan=1>1.547</td><td rowspan=1 colspan=1>9.3%</td></tr><tr><td rowspan=1 colspan=1>32.52</td><td rowspan=1 colspan=1>2.610</td><td rowspan=1 colspan=1>8.0%</td></tr><tr><td rowspan=1 colspan=1>88.87</td><td rowspan=1 colspan=1>6.141</td><td rowspan=1 colspan=1>6.9%</td></tr></table>

# Reference Range

Specimens from 328 presumptively normal donors (including 167 males ranging in age from 19 to 90 years, and 161 females ranging in age from 18 to 66 years) were tested. The results are presented in Table 18.

Table 18: Reference Range   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>tTG IgA</td><td rowspan=1 colspan=1>tTG IgG</td><td rowspan=1 colspan=1>DGP IgA</td><td rowspan=1 colspan=1>DGP IgG</td></tr><tr><td rowspan=1 colspan=1>N (% Positive)</td><td rowspan=1 colspan=1>2 (0.61%)</td><td rowspan=1 colspan=1>2 (0.61%)</td><td rowspan=1 colspan=1>4 (1.22%)</td><td rowspan=1 colspan=1>10 (3.05%)</td></tr><tr><td rowspan=1 colspan=1>Range (U/mL)</td><td rowspan=1 colspan=1>&lt;16.00 - 100.96</td><td rowspan=1 colspan=1>&lt;24.00 - 54.33</td><td rowspan=1 colspan=1>&lt;8.00 - 46.30</td><td rowspan=1 colspan=1>&lt;9.00 - 55.04</td></tr><tr><td rowspan=1 colspan=1>Negative Result (U/mL)</td><td rowspan=1 colspan=1>&lt;20.0</td><td rowspan=1 colspan=1>&lt;36.0</td><td rowspan=1 colspan=1>&lt;15.0</td><td rowspan=1 colspan=1>&lt;13.0</td></tr><tr><td rowspan=1 colspan=1>Positive Result (U/mL)</td><td rowspan=1 colspan=1>‚â•20.0</td><td rowspan=1 colspan=1>‚â•36.0</td><td rowspan=1 colspan=1>‚â•15.0</td><td rowspan=1 colspan=1>‚â•13.0</td></tr></table>

# Conclusion

In conclusion, the Ig_plex Celiac DGP Panel demonstrated performance, safety and effectiveness equivalent or superior to its predicates.